FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study (Q57758065)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22576338%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

title

FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22576338%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1 reference

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22576338%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Roberto Labianca

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22576338%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

author name string

Alberto Zaniboni

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22576338%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Enrico Aitini

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22576338%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Sandro Barni

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22576338%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Daris Ferrari

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22576338%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Vincenzo Catalano

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22576338%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Giuseppe Valmadre

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22576338%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Domenica Ferrara

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22576338%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Enzo Veltri

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22576338%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Claudio Codignola

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22576338%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

publication date

11 May 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22576338%20AND%20SRC:MED&resulttype=core&format=json

Cancer Chemotherapy and Pharmacology

1 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22576338%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

volume

69

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22576338%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22576338%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

page(s)

1641-1645

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22576338%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00280-012-1875-1

1 February 2020

exact match

0 references

cites work

National failure to operate on early stage pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1875-1

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1875-1

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1875-1

Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1875-1

The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1875-1

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1875-1

Optimal two-stage designs for phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1875-1

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1875-1

Second-line therapy for advanced pancreatic cancer: a review of the literature and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1875-1

Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1875-1

Irinotecan plus bolus/infusional 5-Fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia Meridionale.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1875-1

A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1875-1

FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1875-1

Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1875-1

Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1875-1

10.1007/S00280-012-1875-1

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22576338%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1 reference